Literature DB >> 30079761

The Functional Effect of Repeated Cryopreservation on Transduced CD34+ Cells from Patients with Thalassemia.

Garyfalia Karponi1, Penelope-Georgia Papayanni1, Fani Zervou1, Asimina Bouinta2, Achilles Anagnostopoulos1,2, Evangelia Yannaki1,3.   

Abstract

Stable gene marking and effective engraftment of gene-modified CD34+ hematopoietic stem cells is a prerequisite for gene therapy success but may be challenged by the inevitable cryopreservation of the final product prior to extensive quality assurance testing. We investigated the β-globin gene transfer potency in fresh and cryopreserved CD34+ cells from mobilized patients with β-thalassemia, as well as the qualitative impact of repeated freeze/thaw cycles on the functionality of cultured and unmanipulated CD34+ cells in terms of engrafting capacity in a xenotransplantation model, under partial myeloablation. Cells transduced fresh or after one freeze-thaw cycle yielded similar clonogenic and gene transfer frequencies. Repeated cryopreservation cycles did not affect the transduction rates whereas either one or two freeze-thaw cycles of cultured-but not of unmanipulated-cells significantly reduced their clonogenicity. No differences in the engrafting potential of gene-corrected cells subjected to either none or up to two cryopreservation cycles, were encountered post xenotransplantation. Overall, we assessed the gene transfer efficiency, clonogenicity and engrafting capacity of cryopreserved CD34+ cells and the impact of repeated freeze/thaw cycles in their performance. These observations may prove essential in the design of gene therapy trials, considerably facilitating their logistics.

Entities:  

Keywords:  CD34+-cell processing; cryopreservation; engraftment; gene therapy; gene therapy trials; mobilization; thalassemia

Mesh:

Substances:

Year:  2018        PMID: 30079761      PMCID: PMC6206548          DOI: 10.1089/hgtb.2018.032

Source DB:  PubMed          Journal:  Hum Gene Ther Methods        ISSN: 1946-6536            Impact factor:   2.396


  20 in total

1.  Pre infusion, post thaw CD34+ peripheral blood stem cell enumeration as a predictor of haematopoietic engraftment in autologous haematopoietic cell transplantation.

Authors:  James D'Rozario; Robin Parisotto; Jennifer Stapleton; Alison Gidley; David Owen
Journal:  Transfus Apher Sci       Date:  2014-03-12       Impact factor: 1.764

2.  Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products.

Authors:  Kenneth Cornetta; Lisa Duffy; Cameron J Turtle; Michael Jensen; Stephen Forman; Gwendolyn Binder-Scholl; Terry Fry; Anne Chew; David G Maloney; Carl H June
Journal:  Mol Ther       Date:  2017-09-12       Impact factor: 11.454

3.  Hematopoietic stem cell mobilization for gene therapy: superior mobilization by the combination of granulocyte-colony stimulating factor plus plerixafor in patients with β-thalassemia major.

Authors:  Evangelia Yannaki; Garyfalia Karponi; Fani Zervou; Varnavas Constantinou; Asimina Bouinta; Varvara Tachynopoulou; Konstantina Kotta; Erica Jonlin; Thalia Papayannopoulou; Achilles Anagnostopoulos; George Stamatoyannopoulos
Journal:  Hum Gene Ther       Date:  2013-10       Impact factor: 5.695

4.  Superior long-term repopulating capacity of G-CSF+plerixafor-mobilized blood: implications for stem cell gene therapy by studies in the Hbb(th-3) mouse model.

Authors:  Nikoleta Psatha; Eleni Sgouramali; Antonios Gkountis; Athanasios Siametis; Panayotis Baliakas; Varnavas Constantinou; Evangelia Athanasiou; Minas Arsenakis; Achilles Anagnostopoulos; Thalia Papayannopoulou; George Stamatoyannopoulos; Evangelia Yannaki
Journal:  Hum Gene Ther Methods       Date:  2014-12       Impact factor: 2.396

5.  Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia.

Authors:  Alexis A Thompson; Mark C Walters; Janet Kwiatkowski; John E J Rasko; Jean-Antoine Ribeil; Suradej Hongeng; Elisa Magrin; Gary J Schiller; Emmanuel Payen; Michaela Semeraro; Despina Moshous; Francois Lefrere; Hervé Puy; Philippe Bourget; Alessandra Magnani; Laure Caccavelli; Jean-Sébastien Diana; Felipe Suarez; Fabrice Monpoux; Valentine Brousse; Catherine Poirot; Chantal Brouzes; Jean-François Meritet; Corinne Pondarré; Yves Beuzard; Stany Chrétien; Thibaud Lefebvre; David T Teachey; Usanarat Anurathapan; P Joy Ho; Christof von Kalle; Morris Kletzel; Elliott Vichinsky; Sandeep Soni; Gabor Veres; Olivier Negre; Robert W Ross; David Davidson; Alexandria Petrusich; Laura Sandler; Mohammed Asmal; Olivier Hermine; Mariane De Montalembert; Salima Hacein-Bey-Abina; Stéphane Blanche; Philippe Leboulch; Marina Cavazzana
Journal:  N Engl J Med       Date:  2018-04-19       Impact factor: 91.245

6.  Deficiency of oncoretrovirally transduced hematopoietic stem cells and correction through ex vivo expansion.

Authors:  David Bryder; Helga Björgvinsdóttir; Yutaka Sasaki; Sten Eirik W Jacobsen
Journal:  J Gene Med       Date:  2005-02       Impact factor: 4.565

7.  Plerixafor+G-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy.

Authors:  Garyfalia Karponi; Nikoletta Psatha; Carsten Werner Lederer; Jennifer Eileen Adair; Fani Zervou; Nikolaos Zogas; Marina Kleanthous; Constantinos Tsatalas; Achilles Anagnostopoulos; Michel Sadelain; Isabelle Rivière; George Stamatoyannopoulos; Evangelia Yannaki
Journal:  Blood       Date:  2015-06-18       Impact factor: 22.113

8.  High-efficiency recovery of functional hematopoietic progenitor and stem cells from human cord blood cryopreserved for 15 years.

Authors:  Hal E Broxmeyer; Edward F Srour; Giao Hangoc; Scott Cooper; Stacie A Anderson; David M Bodine
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-07       Impact factor: 11.205

9.  A novel competitive repopulation strategy to quantitate engraftment of ex vivo manipulated murine marrow cells in submyeloablated hosts.

Authors:  Brandon K Wyss; Justin L Meyers; Anthony L Sinn; Shanbao Cai; Karen E Pollok; W Scott Goebel
Journal:  Exp Hematol       Date:  2008-02-04       Impact factor: 3.084

10.  Gene therapy for ADA-SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products.

Authors:  Alessandro Aiuti; Maria Grazia Roncarolo; Luigi Naldini
Journal:  EMBO Mol Med       Date:  2017-06       Impact factor: 12.137

View more
  4 in total

1.  Development of a CRISPR/Cas9 system against ruminant animal brucellosis.

Authors:  Garyfalia Karponi; Spyridon K Kritas; Gina Papadopoulou; Elissavet-Kalliopi Akrioti; Eleni Papanikolaou; Evanthia Petridou
Journal:  BMC Vet Res       Date:  2019-11-27       Impact factor: 2.741

2.  Gene Therapy For Beta-Thalassemia: Updated Perspectives.

Authors:  Garyfalia Karponi; Nikolaos Zogas
Journal:  Appl Clin Genet       Date:  2019-09-23

3.  Long-Term Stability and Differentiation Potential of Cryopreserved cGMP-Compliant Human Induced Pluripotent Stem Cells.

Authors:  Mehdi Shafa; Tylor Walsh; Krishna Morgan Panchalingam; Thomas Richardson; Laura Menendez; Xinghui Tian; Sahana Suresh Babu; Saedeh Dadgar; Justin Beller; Fan Yang; Behnam Ahmadian Baghbaderani
Journal:  Int J Mol Sci       Date:  2019-12-23       Impact factor: 5.923

Review 4.  Cryopreservation as a Key Element in the Successful Delivery of Cell-Based Therapies-A Review.

Authors:  Julie Meneghel; Peter Kilbride; G John Morris
Journal:  Front Med (Lausanne)       Date:  2020-11-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.